Quick Answer
MBX Biosciences, Inc. reported Net Income Loss of -$86.97 million for the year ending 2025.
- MBX Biosciences, Inc. showed a decrease of -40.5% in Net Income Loss from 2024 to 2025.
- This data is from MBX Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$5.95 million | Q2 2023: -$7.61 million | Q3 2023: -$10.16 million | Q1 2024: -$12.34 million | Q2 2024: -$15.86 million | Q3 2024: -$18.14 million | Q1 2025: -$23.88 million | Q2 2025: -$19.41 million | Q3 2025: -$21.62 million.
- Over the full 3 years of available data (2023 to 2025), MBX Biosciences, Inc.'s Net Income Loss has declined by 167.1%.
- Historical annual values: Fiscal year 2025: -$86.97 million | Fiscal year 2024: -$61.92 million | Fiscal year 2023: -$32.56 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: